Verve Therapeutics

Acquired

We are on a mission to protect the world from cardiovascular disease

Boston, United States · Founded 2018 · $428.5M raised

Employees
201–500
Founded
2018
Business Model
B2B
Total Funding
$428.5M
Last Round
$213.0M Series COct 2024
Rounds
4
Acquisition Date
Jun 2025

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Verve Therapeutics is a clinical-stage company developing single-course, in vivo gene editing medicines to permanently lower cardiovascular disease risk. Its platform uses base editing to precisely inactivate genes in the liver — such as PCSK9 and ANGPTL3 — that contribute to atherosclerotic cardiovascular disease. Lead programs VERVE-101 and VERVE-102 are advancing through Phase 1b clinical trials with FDA Fast Track Designation.

Summary

Verve Therapeutics is a Biotech company based in Boston, United States, founded in 2018. It has raised $428.5M in total across 4 rounds, most recently a $213.0M Series C round in Oct 2024. Investors include GV, Foresite Capital and ARCH Venture Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

AcquisitionJun 2025

Sign up to see all 6 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series BTotal funding$650.0MOct 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Verve Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/verve-therapeutics"><img src="https://indexed.vc/api/badge/company/verve-therapeutics" alt="Verve Therapeutics on Indexed.vc" width="260" height="76" /></a>